Ionis Pharmaceuticals Inc. (IONS) announced Thursday morning that GlaxoSmithKline (GSK) has decided not to initiate a Phase 3 study to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy.
from RTT - Before the Bell http://ift.tt/1WZWzZK
via IFTTT
No comments:
Post a Comment